Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours

Annals of Internal Medicine

Volumn 126, Issue 8, 1997, Pages 615-620

  Weigner, Marilyn J ^a   Caulfield, Todd A ^a   Danias, Peter G ^b   Silverman, David I ^b   Manning, Warren J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIGOXIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0030978128     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-8-199704150-00005     Document Type: Article

References (35)

1. Heart and Stroke Facts. Statistical Supplement. American Heart Association. Dallas, TX: American Heart Association; 1996:14.
2. Pritchett EL. Management of atrial fibrillation. N Engl J Med. 1992;326: 1264-71.
3. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25:452-9.
4. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-16.
5. Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. "Cardioversion" of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med. 1963;269:325-31.
6. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol. 1989;63:745-6.
7. Peterson P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke. 1986;17:622-6.
8. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19:851-5.
9. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol. 1995;25:1354-61.
10. Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 1993;328:750-5.
11. Stoddard MF, Dawkins P, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J. 1995;129:1204-15.
12. Baer M, Goldschlager N. Atrial fibrillation: an update on new management strategies. Geriatrics. 1995;50:22-9.
13. Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest. 1989;95:118S-27S.
14. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108:352S-9S.
15. Asplund K, Beerman B, Uppsala S, Bergfeldt S, Blomstrom P, Carina B. Treatment of atrial fibrillation. Eur Heart J. 1993;14:1427-33.
16. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J. 1982;104:617-21.
17. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996;93:1262-77.
18. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 1996;125:311-23.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-83.
20. Helmcke F, Nanda NC, Hsiung MC, Soto B, Adey CK, Goyal RG, et al. Color Doppler assessment of mitral regurgitaion with orthogonal planes. Circulation. 1987;75:175-83.
21. Falk RH, Knowlton AA, Bernard SA, Gotleib NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med. 1987;106:503-6.
22. Atwood JE, Sullivan M, Forbes S, Myers J, Pewen W, Olson HG, et al. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1987;10:314-20.
23. Schamroth L. Immediate effects of intravenous verapamil on atrial fibrillation. Cardiovasc Res. 1971;5:419-24.
24. Theisen K, Haufe M, Peters J, Theisen F, Jahrmarker H. Effects of the calcium antagonist diltiazem on atrioventricular conduction in chronic atrial fibrillation. Am J Cardiol. 1985;55:98-102.
25. Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med. 1992;22:351-61.
26. Goldman M. The management of chronic atrial fibrillation: indications for and method of conversion to sinus rhythm. Prog Cardiovasc Dis. 1960;2:465-79.
27. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307-16.
28. Grimm RA, Leung DY, Black IW, Stewart WJ, Thomas JD, Klein AL. Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J. 1995;130:174-6.
29. Manning WJ, Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med. 1995; 155:2193-8.
30. Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation. 1995;92:160-3.
31. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Study. Stroke Prevention in Atrial Fibrillation Investigators. J Stroke Cerebrovasc Dis. 1995; 5:147-57.
32. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-9.
33. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-11.
34. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1993;327:1406-12.
35. Stroke prevention in atrial fibrillation study. Stroke Prevention in Atrial Fibrillation Investigators. Circulation. 1991;84:527-39.